NAMs Technology Partn3Ring webinar series: Session 4

This is the fourth session in our Technology Partn3Ring webinar series focusing on new approach methodologies (NAMs) which are replacement technologies for use in assessing chemical or drug toxicity. This session will include presentations showcasing a synthetic hydrogel and an in vitro 3D cultivation system alongside advanced cell models for safety testing and alternative biological assays.

Speakers and topics

Hear from five developers who will showcase their technologies with the potential to replace the use of animals in assessing chemical or drug toxicity. Attendees will have the opportunity to connect with the speakers, should their work be of interest to their own field of work, to access unique collaboration opportunities. 

DyNAtrix: Programmable viscoelastic matrices for advanced organoid culture and mechanobiology 
Krishna Gupta (Leibniz Institute of Polymer Research, Dresden / Dynamic Matrices i.G.)

• DNANitrix is a non-animal synthetic hydrogel designed to better mimic dynamic human tissue mechanics in cell and organoid culture.
• Krishna is seeking pilot users in organoids, organ‑on‑chip and 3D bioprinting to support validation and qualification for toxicology and disease modelling.

The fertilized avian egg as a partial replacement for genotoxicity testing of environmental chemicals 
Tetyana Cheairs (New York Medical College)

• Prof Cheairs has developed a fertilised avian egg model to partially replace the use of animals in the safety assessment of environmental chemicals.
• Tetyana is seeking collaborators for inter‑laboratory validation and expansion of tested substances and endpoints.

Development of human iPSC-derived hepatocytes for drug discovery, translational research and toxicity testing 
Tom Harris-Brown (bit.bio)

• bit.bio have developed ioHepatocytes, a deterministic, scalable, human iPSC-derived model engineered to enable the industrialisation of NAMs, providing a standardised foundation for highly predictive toxicology and disease modelling.
• Tom is seeking collaborators to integrate ioHepatocytes next-generation systems, ranging from advanced 2D/3D assays to complex microphysiological systems.

Scalable human organoid screening for non-animal drug testing using pillar/perfusion plate technology 
Moo-Yeal Lee (Bioprinting Laboratories Inc.)

• Bioprinting Laboratories have developed a high‑throughput pillar/perfusion plate that enables dynamic 3D culture of spheroids and organoids using bidirectional flow without pumps or tubing.
• Moo-Yeal is looking for collaborators to help qualify biological relevance and define use cases as an alternative to animal models.

Title TBC 
Matthias Gossmann (innoVitro)

• innoVitro have developed the FLEXcyte 96 platform, a high-throughput in vitro system for human‑relevant cardiac safety testing through scalable, biomimetic contractility measurements.
• Matthias is seeking partners with genetically diseased human cardiac cell lines and interest in characterising their lines to support the replacement of humanised animal models of disease.

About Technology Partn3Ring webinars

The NC3Rs Technology Partn3Ring webinars showcase technologies with 3Rs potential to the wider scientific community to identify new partners for further development and use. Open to researchers, clinicians, pharmaceutical and industry professionals, each webinar features short pitches outlining 3Rs research, tools and technologies. Attendees can ask questions and connect with the speakers to access unique collaboration opportunities.